Raj Chovatiya, MD, PhD: Maintaining Optimal Treatment Targets with Upadacitinib for Patients with Atopic Dermatitis
Dr. Chovatiya discusses a recent poster presented at the 2025 Revolutionizing Atopic Dermatitis Conference which evaluated the effectiveness of upadacitinib in achieving long-term maintenance of optimal skin and itch treatment targets in patients with atopic dermatitis. Patients who achieved at least 90 percent improvement in Eczema Area and Severity Index (EASI90) and/or minimal pruritus (Worst Pruritus Numerical Rating Scale score of 0 or 1) at Week 16 were monitored at Weeks 24, 52, 100, and 140 to assess if these scores could be maintained for an extended period of time.
Exploring the Most Effective HCP Marketing Channels
Discover the top HCP marketing channels—from journals to podcasts—and how Matrix Medical Communications delivers strategic, credible engagement.
How to Effectively Advertise to Doctors Through Medical Journals
Discover the most effective strategies for advertising to doctors through trusted medical journals with tips from Matrix Medical Communications.
